Basic Information
| RNALocate ID: | RLID:11001040 |
| RNA Symbol: | hsa-miR-106a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-106a-5p |
| RNA ID: | miRBase:MIMAT0000103 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001467 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001468 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001469 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001470 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001471 | Mitochondrion | Myotube | 27396686 |
| RLID:01001472 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01001473 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001474 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001475 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001476 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001477 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:11001035 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
| RLID:11001036 | Exosome | Sera | 24978137 |
| RLID:11001037 | Exosome | Plasma | 19289371 |
| RLID:11001038 | Exosome | Breast milk | 22211110 |
| RLID:11001039 | Exosome | Brain tissue | 23382797 |
| RLID:11001041 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001042 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11001043 | Exosome | Serum | 25349172 |
| RLID:11001044 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001045 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000302 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001161 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-106a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-03360 |
| MNDR | hsa-miR-106a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-03361 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-03362 |
| MNDR | hsa-miR-106a-5p | Oral squamous cell carcinoma | MNDR-E-MI-03363 |
| MNDR | hsa-miR-106a-5p | Follicular cleaved lymphoma | MNDR-E-MI-03364 |
| MNDR | hsa-miR-106a-5p | Medulloblastoma | MNDR-E-MI-03365 |
| MNDR | hsa-miR-106a-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-03366 |
| MNDR | hsa-miR-106a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-03367 |
| MNDR | hsa-miR-106a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-03368 |
| MNDR | hsa-miR-106a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-03369 |
| MNDR | hsa-miR-106a-5p | Lymphoma | MNDR-E-MI-03370 |
| MNDR | hsa-miR-106a-5p | Lymphoma non-hodgkin | MNDR-E-MI-03371 |
| MNDR | hsa-miR-106a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-03372 |
| MNDR | hsa-miR-106a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-03373 |
| MNDR | hsa-miR-106a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-03374 |
| MNDR | hsa-miR-106a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-03375 |
| MNDR | hsa-miR-106a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-03376 |
| MNDR | hsa-miR-106a-5p | Breast cancer luminal | MNDR-E-MI-03377 |
| MNDR | hsa-miR-106a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-03378 |
| MNDR | hsa-miR-106a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-03379 |
| MNDR | hsa-miR-106a-5p | Small intestine cancer | MNDR-E-MI-03380 |
| MNDR | hsa-miR-106a-5p | Prostate cancer | MNDR-E-MI-03381 |
| MNDR | hsa-miR-106a-5p | Gastric cancer | MNDR-E-MI-03382 |
| MNDR | hsa-miR-106a-5p | Gastric lymphoma | MNDR-E-MI-03383 |
| MNDR | hsa-miR-106a-5p | Alzheimer disease | MNDR-E-MI-03384 |
| MNDR | hsa-miR-106a-5p | Dysautonomia familial | MNDR-E-MI-03385 |
| MNDR | hsa-miR-106a-5p | Leukemia | MNDR-E-MI-03386 |
| MNDR | hsa-miR-106a-5p | Huntington disease | MNDR-E-MI-03387 |
| MNDR | hsa-miR-106a-5p | Chorea | MNDR-E-MI-03388 |
| MNDR | hsa-miR-106a-5p | Carotid stenosis | MNDR-E-MI-03389 |
| MNDR | hsa-miR-106a-5p | Lung cancer | MNDR-E-MI-03390 |
| MNDR | hsa-miR-106a-5p | Fragile x syndrome | MNDR-E-MI-03391 |
| MNDR | hsa-miR-106a-5p | Parkinson disease | MNDR-E-MI-03392 |
| MNDR | hsa-miR-106a-5p | Basal-like breast cancer | MNDR-E-MI-03393 |
| MNDR | hsa-miR-106a-5p | Pancreatic cancer | MNDR-E-MI-03394 |
| MNDR | hsa-miR-106a-5p | Melanoma | MNDR-E-MI-03395 |
| MNDR | hsa-miR-106a-5p | Lesch-nyhan syndrome | MNDR-E-MI-03396 |
| MNDR | hsa-miR-106a-5p | Rectum adenocarcinoma | MNDR-E-MI-03397 |
| MNDR | hsa-miR-106a-5p | Hepatitis B | MNDR-E-MI-03398 |
| MNDR | hsa-miR-106a-5p | Epithelial ovarian cancer | MNDR-E-MI-03399 |
| MNDR | hsa-miR-106a-5p | Nephroblastoma | MNDR-E-MI-03400 |
| MNDR | hsa-miR-106a-5p | Colon cancer | MNDR-E-MI-03401 |
| MNDR | hsa-miR-106a-5p | Ischemic attack transient | MNDR-E-MI-03402 |
| MNDR | hsa-miR-106a-5p | Colon adenocarcinoma | MNDR-E-MI-03403 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis | MNDR-E-MI-03404 |
| MNDR | hsa-miR-106a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-03405 |
| MNDR | hsa-miR-106a-5p | Familial ovarian cancer | MNDR-E-MI-03406 |
| MNDR | hsa-miR-106a-5p | Prostate adenocarcinoma | MNDR-E-MI-03407 |
| MNDR | hsa-miR-106a-5p | Kidney cancer | MNDR-E-MI-03408 |
| MNDR | hsa-miR-106a-5p | Carcinoma ductal breast | MNDR-E-MI-03409 |
| MNDR | hsa-miR-106a-5p | Glioblastoma | MNDR-E-MI-03410 |
| MNDR | hsa-miR-106a-5p | Astrocytoma | MNDR-E-MI-03411 |
| MNDR | hsa-miR-106a-5p | Glioma | MNDR-E-MI-03412 |
| MNDR | hsa-miR-106a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-03413 |
| MNDR | hsa-miR-106a-5p | Epilepsy temporal lobe | MNDR-E-MI-03414 |
| MNDR | hsa-miR-106a-5p | Osteosarcoma | MNDR-E-MI-03415 |
| MNDR | hsa-miR-106a-5p | Liposarcoma | MNDR-E-MI-03416 |
| MNDR | hsa-miR-106a-5p | Meningioma | MNDR-E-MI-03417 |
| MNDR | hsa-miR-106a-5p | Liver cancer | MNDR-E-MI-03418 |
| MNDR | hsa-miR-106a-5p | Cervical adenocarcinoma | MNDR-E-MI-03419 |
| MNDR | hsa-miR-106a-5p | Gastric adenocarcinoma | MNDR-E-MI-03420 |
| MNDR | hsa-miR-106a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-03421 |
| MNDR | hsa-miR-106a-5p | Lung squamous cell carcinoma | MNDR-E-MI-03422 |
| MNDR | hsa-miR-106a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-03423 |
| MNDR | hsa-miR-106a-5p | Lung adenocarcinoma | MNDR-E-MI-03424 |
| MNDR | hsa-miR-106a-5p | Thyroid carcinoma | MNDR-E-MI-03425 |
| MNDR | hsa-miR-106a-5p | Ovarian carcinoma | MNDR-E-MI-03426 |
| MNDR | hsa-miR-106a-5p | Bladder urothelial carcinoma | MNDR-E-MI-03427 |
| MNDR | hsa-miR-106a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-03428 |
| MNDR | hsa-miR-106a-5p | Carcinoma renal cell | MNDR-E-MI-03429 |
| MNDR | hsa-miR-106a-5p | Papillary renal cell carcinoma | MNDR-E-MI-03430 |
| MNDR | hsa-miR-106a-5p | Clear cell renal cell cancer | MNDR-E-MI-03431 |
| MNDR | hsa-miR-106a-5p | Biliary tract cancer | MNDR-E-MI-03432 |
| MNDR | hsa-miR-106a-5p | Cholangiocarcinoma | MNDR-E-MI-03433 |
| MNDR | hsa-miR-106a-5p | Esophageal cancer | MNDR-E-MI-03434 |
| MNDR | hsa-miR-106a-5p | Lung small cell carcinoma | MNDR-E-MI-03435 |
| MNDR | hsa-miR-106a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-03436 |
| MNDR | hsa-miR-106a-5p | Testicular germ cell cancer | MNDR-E-MI-03437 |
| MNDR | hsa-miR-106a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-03438 |
| MNDR | hsa-miR-106a-5p | Acute t cell leukemia | MNDR-E-MI-03439 |
| MNDR | hsa-miR-106a-5p | Acute heart failure | MNDR-E-MI-03440 |
| MNDR | hsa-miR-106a-5p | Aortic valve disease | MNDR-E-MI-03441 |
| MNDR | hsa-miR-106a-5p | Adenoma | MNDR-E-MI-03442 |
| MNDR | hsa-miR-106a-5p | Breast invasive carcinoma | MNDR-E-MI-03443 |
| MNDR | hsa-miR-106a-5p | Hepatocellular carcinoma | MNDR-E-MI-03444 |
| MNDR | hsa-miR-106a-5p | Embryonal cancer | MNDR-E-MI-03445 |
| MNDR | hsa-miR-106a-5p | Familiar ovarian carcinoma | MNDR-E-MI-03446 |
| MNDR | hsa-miR-106a-5p | B-cell lymphoma | MNDR-E-MI-03447 |
| MNDR | hsa-miR-106a-5p | T-cell leukemia | MNDR-E-MI-03448 |
| MNDR | hsa-miR-106a-5p | Neuroblastoma | MNDR-E-MI-03449 |
| MNDR | hsa-miR-106a-5p | Burkitt lymphoma | MNDR-E-MI-03450 |
| MNDR | hsa-miR-106a-5p | Psoriasis | MNDR-E-MI-03451 |
| MNDR | hsa-miR-106a-5p | Acute myelocytic leukemia | MNDR-E-MI-03452 |
| MNDR | hsa-miR-106a-5p | Colorectal cancer | MNDR-E-MI-03453 |
| MNDR | hsa-miR-106a-5p | Multiple myeloma | MNDR-E-MI-03454 |
| MNDR | hsa-miR-106a-5p | Ependymoma | MNDR-E-MI-03455 |
| MNDR | hsa-miR-106a-5p | Prostatic neoplasms | MNDR-E-MI-03456 |
| MNDR | hsa-miR-106a-5p | Pseudorabies | MNDR-E-MI-03457 |
| MNDR | hsa-miR-106a-5p | Hypersomnolence idiopathic | MNDR-E-MI-03458 |
| MNDR | hsa-miR-106a-5p | Arsenic poisoning | MNDR-E-MI-03459 |
| MNDR | hsa-miR-106a-5p | Stroke lacunar | MNDR-E-MI-03460 |
| MNDR | hsa-miR-106a-5p | Duke C | MNDR-E-MI-03461 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABHD2 | Homo sapiens | RR00026071 |
TOP